Acute SAH from a ruptured intracranial aneurysm contributes for 30% of all hemorrhagic strokes. The bleeding itself occurs in the subarachnoid space. Nevertheless, injury to the brain parenchyma occurs as a consequence of the bleeding, directly, via several well-defined mechanisms and pathways, but also indirectly, or secondarily. This secondary brain injury following SAH has a variety of causes and possible mechanisms. Amongst others, inflammatory events have been shown to occur in parallel to, contribute to, or even to initiate programmed cell death (PCD) within the central nervous system (CNS) in human and animal studies alike.
Mechanisms of secondary brain injury are of utmost interest not only to scientists, but also to clinicians, as they often provide possibilities for translational approaches as well as distinct time windows for tailored treatment options.
In this article, we review secondary brain injury due to inflammatory changes, that occur on cellular, as well as on molecular level in the various different compartments of the CNS: the brain vessels, the subarachnoid space, and the brain parenchyma itself and hypothesize about possible signaling mechanisms between these compartments.
Keywords: Subarachnoid hemorrhage, inflammation, secondary brain injury, microglia, neuronal cell death, secondary brain injury.
Recent Advances in Pathophysiology of Traumatic Brain Injury
Current Neuropharmacology Respiratory Hypoxia and Oxidative Stress in the Brain. Is the Endogenous Erythropoietin an Antioxidant?
Current Chemical Biology Cutting-edge Patents in Alzheimers Disease Drug Discovery: Anticipation of Potential Future Treatments
Recent Patents on CNS Drug Discovery (Discontinued) Effects of Coenzyme Q and Creatine Supplementation on Brain Energy Metabolism in Rats Exposed to Chronic Cerebral Hypoperfusion
Current Alzheimer Research The Rabbit Syndrome: State of the Art
Current Clinical Pharmacology Oxidative Stress: Major Threat in Traumatic Brain Injury
CNS & Neurological Disorders - Drug Targets Glycans and Glycan-Binding Proteins in Brain: Galectin-1-Induced Expression of Neurotrophic Factors in Astrocytes
Current Drug Targets Renin-angiotensin System Blockers and Modulation of Radiation-Induced Brain Injury
Current Drug Targets Unmasking Sex-Based Disparity in Neuronal Metabolism
Current Pharmaceutical Design Exogenous Progesterone: A Potential Therapeutic Candidate in CNS Injury and Neurodegeneration
Current Medicinal Chemistry Pituitary Adenylate Cyclase-Activating Polypeptide: Focus on Structure- Activity Relationships of a Neuroprotective Peptide
Current Medicinal Chemistry Heme Oxygenase-2 Protects Against Glutathione Depletion-induced Neuronal Apoptosis Mediated by Bilirubin and Cyclic GMP
Current Neurovascular Research The Cannabinoid CB2 Receptor as a Target for Inflammation-Dependent Neurodegeneration
Current Neuropharmacology Ginsenoside RB1 Reduces Neurologic Damage, is Anti-Apoptotic, and Down-Regulates p53 and BAX in Subarachnoid Hemorrhage
Current Neurovascular Research The Mechanism of Exosomes Function in Neurological Diseases: A Progressive Review
Current Pharmaceutical Design Pharmacological Treatment of Hypoxic-Ischemic Reperfusion Injury of the Newborn Brain in the Clinical Setting: What are the Possibilities in the Near Future?
Current Pediatric Reviews Magnetic Resonance Spectroscopy Biomarkers in Term Perinatal Asphyxial Encephalopathy: From Neuropathological Correlates to Future Clinical Applications
Current Pediatric Reviews The Cholinergic Potential, the Vagus Nerve and Challenges in Treatment of Traumatic Brain Injury
Current Pharmaceutical Design Anti-inflammatory strategies in stroke: a potential therapeutic target
Current Vascular Pharmacology Pituitary Adenylate Cyclase Activating Polypeptide: A Potential Neuroprotective Peptide
Current Pharmaceutical Design